drugset
drugset / Trial / NCT02775591

Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms

NCT02775591 ↗

Phase 4 Completed 147 enrolled Seoul National University Hospital Hanyang University · collabKorea University Guro Hospital · collabSMG-SNU Boramae Medical Center · collabSamsung Medical Center · collabSeoul Veterans Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether DA-9701(Motilitone) is effective and safe for the treatment on health-related quality of life in Parkinson's disease (PD) patients with gastrointestinal symptoms.

Timeline

Start
2016-04
Primary completion
2018-06
Completion
2018-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject LUCORIDALINES Unknown 30 mg —

Indications

Parkinson disease dyspepsia